First experience of magnetically levitated extracorporeal left ventricular assist device for cardiogenic shock in China

ESC Heart Fail. 2022 Apr;9(2):1471-1473. doi: 10.1002/ehf2.13769. Epub 2022 Jan 3.

Abstract

We report the first case of an investigational maglev extracorporeal ventricular assist device (extra-VAD) use in China for a patient with cardiogenic shock post-coronary artery bypass surgery. There were no extra-VAD devices available for clinical use in China. The patient was successfully supported for 9 days and recovered to hospital discharge. Throughout the support, the patient's haemodynamic and haematologic parameters demonstrated good patient recovery and no device-related complications were observed. Our results encourage extra-VAD use in short-term to mid-term bridging the cardiogenic shock patients in China and potentially other developing countries for both clinical and health economic benefits.

Keywords: Cardiogenic shock; Extracorporeal ventricular assist device; Maglev.

Publication types

  • Case Reports

MeSH terms

  • China
  • Heart-Assist Devices* / adverse effects
  • Hemodynamics
  • Humans
  • Shock, Cardiogenic* / etiology
  • Shock, Cardiogenic* / surgery
  • Treatment Outcome